It has been studied that PD-L1 antibody is loaded with engineered tumor symbiotic bacterial membrane nanovesicles to realize precise immunochemotherapy in a mouse CRC model [156], and the feasibility of reversing immunotherapy resistance with key bacteria, such as F. nucleatum, as targets has been verified. This evidence concerns the gene CD274 and colorectal carcinoma.